Clinical Trials/NCT00373776

NCT00373776

Completed

Phase 1

Miltefosine for Mucosal Leishmaniasis

AB Foundation0 sites75 target enrollmentApril 2004

ConditionsLeishmaniasis

Drugsmiltefosine 2.5 mg/kg/day for 28 days

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Leishmaniasis
Sponsor: AB Foundation
Enrollment: 75
Primary Endpoint: Efficacy
Status: Completed
Last Updated: 19 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Detailed Description

Treat bolivian mucosal leishmaniasis with miltefosine.

Registry

clinicaltrials.gov

Start Date

April 2004

End Date

May 2006

Last Updated

19 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

AB Foundation

Eligibility Criteria

Inclusion Criteria

•Mucosal leishmaniasis

Exclusion Criteria

•Abnormal liver function tests (LFT)
•Abnormal kidney function test
•Concomitant diseases

Outcomes

Primary Outcomes

Efficacy

Secondary Outcomes

toxicity

Similar Trials

Completed

Phase 2

Miltefosine to Treat Mucocutaneous LeishmaniasisMucosal LeishmaniasisCutaneous Leishmaniasis

NCT01050907Knight Therapeutics (USA) Inc4

Completed

Phase 1

Miltefosine (Long Course) for Bolivian Mucosal LeishmaniasisLeishmaniasis

NCT00373568AB Foundation25

Completed

Phase 2

Clinical Trial of Miltefosine to Treat Mucosal LeishmaniasisLeishmaniasisLeishmaniasis, Mucocutaneous

NCT01377974Brasilia University Hospital40

Unknown

Not Applicable

Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective StudyCutaneous LeishmaniasesTreatment AdherencePrimary Health CareDrug Evaluation

NCT05493059Centre Hospitalier de Cayenne20

Completed

Phase 2

Miltefosine to Treat Cutaneous Leishmaniasis in BoliviaCutaneous Leishmaniasis

NCT00233545AB Foundation80